Table 2 Proportion of COVID-19 patients with resistant co-infections
First author | Disease presentation | Patients screened (No.) | SARS-CoV-2 patients (No.) | Number of patients with co-infections (%)* | Number of patients with resistant co-infections (%)* |
|---|---|---|---|---|---|
Chowdhary [31] | BSI | 596 | 596 | 15 (2.5%) | 10 (1.7%) |
Bogossian [44] | COVID-19 | 75 | 69 | 24 (34%) | 23 (33%) |
Ramadan [33] | COVID-19 | 260 | 260 | 28 (11%) | 28 (11%) |
Amarsy [45] | BSI, Respiratory Distress | 96 | 95 | 4 (45%) | 4 (4%) |
Perez [19] | VAP, VAP with bacteremia, bacteremia, bone or soft tissue infections | 34 | 17 | 17 (100%) | 17 (100%) |
Salehi [22] | OPC | 1059 | 1059 | 53 (5.0%) | 2 (0.2%) |
Cataldo [46] | BSI | 57 | 57 | 28 (49%) | 9 (16%) |
Posteraro [47] | 79 M with complicated T2DM who had fever, necrotic and ulcerative lesions on the amputated leg stump, BSI | 1 | 1 | 1 (100%) | 1 (100%) |
Nori [3] | COVID-19 and subsequent positive microbiological results (within 30 days) | 4267 | 4267 | 152 (3.6%) | 25 (0.6%) † |
Mahmoudi [48] | COVID-19 patients assessed for bacterial infections | 340 | 340 | 43 (13%) | 31 (72%) |
Li [49] | Lung, BSI and UTI | 1495 | 1495 | 102 (6.8%) | 102 (6.8%)‡ |
Contou [18] | All microbiological investigations performed within the first 48 h of ICU admission were reviewed | 92 | 92 | 26 (28%) | 7 (8%)§ |
Mo [22] | COVID-19 patients who received Tocilizumab | 617 | 38 | 15 (39%) | 11 (29%) |
Garcia-Menino [8] | Suspected or confirmed COVID-19 Patients | 62 | 62 | 7 (11%) | 7 (11%) |
Sharifipour [20] | COVID-19 Patients | 19 | 19 | 19 (100%) | 17 (89%) |
Walpole [50] | 33 M with fever for 3 days, abdominal pain for 1 day and one episode of vomiting | 1 | 1 | 1 (100%) | 1 (100%) |
Razazi [10] | Viral ARDS | 3821 | 90 | NA | 21 (23%) |
Guisado-Gil [17] | Hospital-acquired Candidemia and MDR BSI | 282 | 282 | NA¶ | NA¶ |
Montrucchio [51] | COVID patients screened for carbapenemase-producing K. pneumoniae | 35 | 7 | 6 (86%) | 6 (86%) |
Mady [23] | COVID-19 patients with ARDS receiving tocilizumab | 61 | 61 | 12 (20%) | 3 (5%) |
Tiri [52] | Patients admitted to ICU screened using rectal swabs or clinical cultures for CRE | 62 | 62 | 17 (27%) | 17 (27%) |
Perrotta [54] | 57 M admitted to hematology with K. pneumoniae NDM sepsis | 1 | 1 | 1 (100%) | 1 (100%) |
Baiou [55] | Critical COVID-19 Patients | 1231 | 234 | 78 (6%) | NA |
Segrelles-Calvo [56] | Adult patients admitted to ICU or RICU | 215 | 215 | 7 (3%) | NA |
Martinez-Guerra [57] | Severe COVID-19 patients | 794 | 794 | 74 (11%) | 127 (20%)†† |
Karruli [58] | Critically Ill COVID-19 Patients | 32 | 32 | NA/32 | 16 (50%) |
Gomez-Simmonds [60] | Secondary CPE infections in COVID-19 patients | 3152 | 3152 | NA | 13 (0.4%) |
Cultrera [61] | COVID-19 patients admitted in ICU and non-COVID-19 ICU settings | NA | NA | 28 | NA |
Khurana [62] | Severely ill COVID-19 patients | 1179 | 1179 | 151 (13%) | 105 (9%) |
Posteraro [70] | BSI in COVID-19 patients | 293 | 293 | 46 (16%) | 12 (5%) |
Pascale [63] | > 18 years admitted to ICU | 1151 | 1151 | NA/1151 | 23 (1.8%) |
Baskaran [64] | COVID-19 patients in ICU | 579 | 254 | 83 (33%) | NA/254 |
Moretti [65] | Patients with COVID-19 and VAP | 39 | 39 | 21 (54%) | 67%# |
Grasselli [66] | Patients with COVID-19 pneumonia | 813 | 813 | 359 (44%) | 38%** |
Magnasco [67] | Patients with severe COVID-19 | 118 | 118 | NA/118 | 14 (12%) |
Bentivegna [68] | Patients in COVID-19 Departments | NA | NA | NA/NA | 150/NA |
Suarez-de-la-Rica [69] | Mechanically ventilated critically ill COVID-19 patients | 107 | 107 | 46 (43%) | 17 (16%) |
Kokkoris [42] | BSI in COVID-19 patients | 50 | 50 | 27 (54%) | 17 (34%)‡‡ |
TOTAL | 23,086 | 16,602 |